On clinical trial fragility due to patients lost to follow up

Abstract Background Clinical trials routinely have patients lost to follow up. We propose a methodology to understand their possible effect on the results of statistical tests by altering the concept of the fragility index to treat the outcomes of observed patients as fixed but incorporate the poten...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Benjamin R. Baer, Stephen E. Fremes, Mario Gaudino, Mary Charlson, Martin T. Wells
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
Acceso en línea:https://doaj.org/article/bf76edffb4524432be3b3cc45054d90e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:bf76edffb4524432be3b3cc45054d90e
record_format dspace
spelling oai:doaj.org-article:bf76edffb4524432be3b3cc45054d90e2021-11-21T12:40:35ZOn clinical trial fragility due to patients lost to follow up10.1186/s12874-021-01446-z1471-2288https://doaj.org/article/bf76edffb4524432be3b3cc45054d90e2021-11-01T00:00:00Zhttps://doi.org/10.1186/s12874-021-01446-zhttps://doaj.org/toc/1471-2288Abstract Background Clinical trials routinely have patients lost to follow up. We propose a methodology to understand their possible effect on the results of statistical tests by altering the concept of the fragility index to treat the outcomes of observed patients as fixed but incorporate the potential outcomes of patients lost to follow up as random and subject to modification. Methods We reanalyse the statistical results of three clinical trials on coronary artery bypass grafting (CABG) to study the possible effect of patients lost to follow up on the treatment effect statistical significance. To do so, we introduce the LTFU-aware fragility indices as a measure of the robustness of a clinical trial’s statistical results with respect to patients lost to follow up. Results The analyses illustrate that clinical trials can either be completely robust to the outcomes of patients lost to follow up, extremely sensitive to the outcomes of patients lost to follow up, or in an intermediate state. When a clinical trial is in an intermediate state, the LTFU-aware fragility indices provide an interpretable measure to quantify the degree of fragility or robustness. Conclusions The LTFU-aware fragility indices allow researchers to rigorously explore the outcomes of patients who are lost to follow up, when their data is the appropriate kind. The LTFU-aware fragility indices are sensitivity measures in a way that the original fragility index is not.Benjamin R. BaerStephen E. FremesMario GaudinoMary CharlsonMartin T. WellsBMCarticleFragility indexStatistical significanceResearch methodsLoss to follow upSensitivity analysisCABGMedicine (General)R5-920ENBMC Medical Research Methodology, Vol 21, Iss 1, Pp 1-11 (2021)
institution DOAJ
collection DOAJ
language EN
topic Fragility index
Statistical significance
Research methods
Loss to follow up
Sensitivity analysis
CABG
Medicine (General)
R5-920
spellingShingle Fragility index
Statistical significance
Research methods
Loss to follow up
Sensitivity analysis
CABG
Medicine (General)
R5-920
Benjamin R. Baer
Stephen E. Fremes
Mario Gaudino
Mary Charlson
Martin T. Wells
On clinical trial fragility due to patients lost to follow up
description Abstract Background Clinical trials routinely have patients lost to follow up. We propose a methodology to understand their possible effect on the results of statistical tests by altering the concept of the fragility index to treat the outcomes of observed patients as fixed but incorporate the potential outcomes of patients lost to follow up as random and subject to modification. Methods We reanalyse the statistical results of three clinical trials on coronary artery bypass grafting (CABG) to study the possible effect of patients lost to follow up on the treatment effect statistical significance. To do so, we introduce the LTFU-aware fragility indices as a measure of the robustness of a clinical trial’s statistical results with respect to patients lost to follow up. Results The analyses illustrate that clinical trials can either be completely robust to the outcomes of patients lost to follow up, extremely sensitive to the outcomes of patients lost to follow up, or in an intermediate state. When a clinical trial is in an intermediate state, the LTFU-aware fragility indices provide an interpretable measure to quantify the degree of fragility or robustness. Conclusions The LTFU-aware fragility indices allow researchers to rigorously explore the outcomes of patients who are lost to follow up, when their data is the appropriate kind. The LTFU-aware fragility indices are sensitivity measures in a way that the original fragility index is not.
format article
author Benjamin R. Baer
Stephen E. Fremes
Mario Gaudino
Mary Charlson
Martin T. Wells
author_facet Benjamin R. Baer
Stephen E. Fremes
Mario Gaudino
Mary Charlson
Martin T. Wells
author_sort Benjamin R. Baer
title On clinical trial fragility due to patients lost to follow up
title_short On clinical trial fragility due to patients lost to follow up
title_full On clinical trial fragility due to patients lost to follow up
title_fullStr On clinical trial fragility due to patients lost to follow up
title_full_unstemmed On clinical trial fragility due to patients lost to follow up
title_sort on clinical trial fragility due to patients lost to follow up
publisher BMC
publishDate 2021
url https://doaj.org/article/bf76edffb4524432be3b3cc45054d90e
work_keys_str_mv AT benjaminrbaer onclinicaltrialfragilityduetopatientslosttofollowup
AT stephenefremes onclinicaltrialfragilityduetopatientslosttofollowup
AT mariogaudino onclinicaltrialfragilityduetopatientslosttofollowup
AT marycharlson onclinicaltrialfragilityduetopatientslosttofollowup
AT martintwells onclinicaltrialfragilityduetopatientslosttofollowup
_version_ 1718418912533544960